A research group led by Professor Hideyoshi Harashima and Associate Professor Yusuke Sato (Graduate School of Pharmaceutical Sciences, Hokkaido University) developed lipid nanoparticles (LNP*1) targeting immune cells in the spleen and demonstrated their safety and efficacy as an mRNA vaccine formulation. For more information, please click here.

•  Achieved spleen-selective mRNA delivery by adjusting lipid nanoparticle composition ratio.
•  Elucidated the involvement of the complement-complement receptor pathway in the uptake mechanism of mRNA into B cells in the spleen.
• Demonstrated the safety and efficacy of an mRNA vaccine targeting immune cells in the spleen.